Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis ; volume:58 ; number:4 ; day:17 ; month:4 ; year:2024 ; pages:600-609 ; date:7.2024
Therapeutic innovation & regulatory science ; 58, Heft 4 (17.4.2024), 600-609, 7.2024
- Creator
-
Signorovitch, James
Zhang, Jialu
Brown, David
Dunnmon, Preston
Xiu, Liang
Done, Nicolae
Hsu, Kristen
Barbachano, Yolanda
Lousada, Isabelle
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s43441-024-00641-6
- URN
-
urn:nbn:de:101:1-2408182126485.506439794893
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Signorovitch, James
- Zhang, Jialu
- Brown, David
- Dunnmon, Preston
- Xiu, Liang
- Done, Nicolae
- Hsu, Kristen
- Barbachano, Yolanda
- Lousada, Isabelle
- SpringerLink (Online service)
Other Objects (12)
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
![Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks
Structural analysis of ex vivo amyloid fibrils from AL amyloidosis
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks
Structural analysis of ex vivo amyloid fibrils from AL amyloidosis
Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
Global epidemiology of amyloid light-chain amyloidosis
Amyloid β [beta] aggregation - insights from models for inducible β [beta] amyloidosis
Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
The overall structure of the multi-domain amyloid precursor protein
AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
Modified amyloid variants in pathological subgroups of β‐amyloidosis
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder
Particle-based solid for nonsmooth multidomain dynamics
Robust machine translation for multi-domain tasks